Calamos Advisors LLC Acquires New Stake in TG Therapeutics, Inc. $TGTX

Calamos Advisors LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 22,954 shares of the biopharmaceutical company's stock, valued at approximately $1,280,000.

Several other institutional investors have also recently made changes to their positions in TGTX. BlackRock Inc. bought a new position in shares of TG Therapeutics in the 2nd quarter worth about $1,211,429,000. Bank of America Corp DE grew its position in TG Therapeutics by 71.7% in the 1st quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company's stock worth $48,544,000 after purchasing an additional 610,195 shares during the period. Dimensional Fund Advisors LP increased its position in TG Therapeutics by 129.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company's stock valued at $36,029,000 after acquiring an additional 612,068 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of TG Therapeutics during the 2nd quarter valued at about $49,472,000. Finally, Wellington Management Group LLP raised its position in TG Therapeutics by 697.6% in the second quarter. Wellington Management Group LLP now owns 478,265 shares of the biopharmaceutical company's stock worth $26,276,000 after acquiring an additional 418,300 shares during the period. Institutional investors own 58.58% of the company's stock.

Trending Headlines about TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Third-quarter revenue was $259.9 million, up 60.8% year over year and above estimates of about $245.5 million. TG Therapeutics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its 2026 revenue outlook to $1.0 billion, ahead of the roughly $961 million consensus. CEO Michael Weiss also said global revenue could exceed $1 billion, with BRIUMVI driving growth. TG Therapeutics CEO sees global revenue exceeding $1B in 2026
• Neutral Sentiment: EPS was $0.35. That topped Zacks’ $0.28 estimate, but was below other reported consensus figures around $0.37; earnings were also lower than the $2.43 reported a year earlier. TG Therapeutics beats Q3 earnings and revenue estimates

Analysts Set New Price Targets

Several brokerages recently weighed in on TGTX. JPMorgan Chase & Co. upped their target price on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Zacks Research raised shares of TG Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Wednesday, November 4th. HC Wainwright reaffirmed a "buy" rating and issued a $78.00 price target on shares of TG Therapeutics in a report on Tuesday, September 1st. Weiss Ratings upgraded TG Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Wednesday, November 4th. Finally, B. Riley Financial boosted their price objective on TG Therapeutics from $55.00 to $86.00 and gave the stock a "buy" rating in a research note on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $63.00.

TG Therapeutics Stock Up 5.9%

Shares of TGTX opened at $63.38 on Tuesday. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $9.70 billion, a P/E ratio of 23.13, a P/E/G ratio of 2.60 and a beta of 1.89. The firm has a fifty day moving average price of $55.99 and a 200-day moving average price of $44.66. TG Therapeutics, Inc. has a 12-month low of $26.76 and a 12-month high of $63.60.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.02). The company had revenue of $259.94 million for the quarter, compared to the consensus estimate of $245.47 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business's revenue was up 60.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.43 EPS. Equities research analysts expect that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.

Insider Activity at TG Therapeutics

In other news, Director Laurence Charney sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the sale, the director owned 168,640 shares of the company's stock, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.87% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.

The company's marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI's availability into international markets, including Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.